Aurinia Pharmaceuticals Inc.
NASDAQ:AUPHBiotechnology
+$0.13 today
- Market cap
- $2.03B
- Beta
- 1.43
- P/E (TTM)
- 7.2
- EPS (TTM)
- $2.25
Volume 0.76M
Average 1.21M
AUPH Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Aurinia Pharmaceuticals Inc.NASDAQ: AUPH
Net Income · Q2 FY2026 · quarter ended Jun 2026
Net income grows, but more slowly than its trailing trend
Q2 FY2026 net income of $37.41M rose 73.9% year over year, behind the +418.0% change in trailing-twelve-month net income. Sequentially, it rose 8.9% from the prior quarter.
Context
- Net income amounted to 101.5% of revenue in FY2025, up 99.0 pp from a year earlier.
- Net income increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 3 analysts of $131.56M (-54.2%) for the fiscal year ending Dec 2026, a slowdown from the +4893.1% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $37.41M+8.9% QoQ
- Last fiscal yearDec 2025
- $287.2M+4893.1% YoY
- LTMJun 2026
- $314.11M+418.0% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +73.9% | -5.7% | -79.7 pp |
| 1 year | +4893.1% | -54.2% | -4947.3 pp |
| 3-year CAGR | — | -14.5% | — |
| 5-year CAGR | -1.2% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- 287.2M USD
- Year-over-year change
- +4893.1%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 287.2M | +4893.1% |
| FY2024 | 2024-12-31 | 5.75M | +107.4% |
| FY2023 | 2023-12-31 | (78.02M) | +27.9% |
| FY2022 | 2022-12-31 | (108.18M) | +40.2% |
| FY2021 | 2021-12-31 | (180.97M) | — |
Net Income vs competitors
How AUPH compares with its peers on the latest reported figures
- AUPH's LTM Jun 2026 net income of $314.11M is the 4th largest of the 10 companies compared; the peer median is $166.09M.
- Its year-over-year change of +418.0% is the highest of 9, against a peer median of +55.8%.
- Net income amounts to 100.8% of revenue for AUPH, versus a peer median of 2671.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $586.84M | -23.5% | +9.0% | — | |
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | $438.96M | +92.9% | +29.5% | 5933.5% |
| LTM Jun 2026 | $401.9M | +84.1% | +49.8% | — | |
| LTM Jun 2026 | $314.11M | +418.0% | — | 100.8% | |
| LTM Mar 2026 | $259.47M | +76.5% | +66.1% | — | |
TRAXFirst Tracks Biotherapeutics Inc | FY2025 | $166.09M | +1.5% | — | — |
| LTM Mar 2026 | $78.15M | +141.3% | -19.7% | — | |
EVMNEvommune, Inc. | LTM Mar 2026 | $75.99M | — | — | 759.9% |
| LTM Mar 2026 | $69.66M | -46.5% | -9.3% | 832.6% | |
| FY2025 | $60.9M | +35.2% | — | 4511.0% | |
| Peer median (excluding AUPH) | $166.09M | +55.8% | +19.3% | 2671.8% | |
Competitors are the stored peer set for AUPH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (180.97M) | (108.18M) | (78.02M) | 5.75M | 287.2M |
| Depreciation & Amortization | 2.76M | 2.71M | 11.65M | 19.45M | 9.27M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | (176.19M) |
| Stock-Based Compensation | 31.24M | 32.3M | 45.31M | 31.6M | 14.68M |
| Change in Working Capital | (21.63M) | (6.82M) | (5.61M) | 5.45M | (8.78M) |
| Accounts Receivables | (15.42M) | 1.93M | (10.61M) | (12.46M) | (4.91M) |
| Inventory | (5.64M) | (9.07M) | (15.87M) | 477K | (6.46M) |
| Accounts Payables | 4.08M | (792K) | 1.24M | 860K | (1.87M) |
| Other Working Capital | (4.65M) | 1.12M | 19.63M | 16.57M | 4.46M |
| Other Non-Cash Items | 10.9M | 462K | (6.79M) | (17.85M) | 9.49M |
| Operating Cash Flow | (157.69M) | (79.53M) | (33.46M) | 44.39M | 135.66M |
| Capital Expenditures | (1.5M) | (292K) | (718K) | (281K) | (252K) |
| Acquisitions (Net) | (1.2M) | 0 | 0 | 0 | 0 |
| Purchases of Investments | (438.96M) | (523.99M) | (523.5M) | (545.83M) | (526.65M) |
| Sales of Investments | 354.43M | 464.32M | 529.38M | 585.42M | 494.13M |
| Other Investing Activities | (16.63M) | (663K) | (11.86M) | (43K) | 0 |
| Investing Cash Flow | (103.87M) | (60.63M) | (6.71M) | 39.26M | (32.77M) |
| Debt Repayment | 0 | 0 | (10.03M) | (11.99M) | (13.14M) |
| Common Stock Issued | 196.74M | 0 | 0 | 0 | 14.95M |
| Common Stock Repurchased | 0 | 0 | 0 | (40.24M) | (98.16M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 24.37M | 2.43M | 4.9M | 3.14M | (9.76M) |
| Financing Cash Flow | 221.11M | 2.43M | (5.13M) | (49.09M) | (106.11M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (40.45M) | (137.73M) | (45.3M) | 34.56M | (3.22M) |
| Free Cash Flow | (159.19M) | (79.82M) | (34.18M) | 44.11M | 135.41M |
Aurinia Pharmaceuticals Inc.
NASDAQ:AUPH
Intrinsic Alpha fair value
Locked
Current Price
$15.13
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.